The science of the Sinclair Method

A Finnish discovery

The Sinclair Method began at Alko, the Finnish state alcohol research institute, where Dr John David Sinclair spent decades studying how alcohol reinforced drinking behaviour in laboratory animals. He published the theoretical groundwork in 1992 and the first full clinical protocol followed shortly after. The central insight was counterintuitive: rather than trying to stop someone drinking, you pair their drinking with an opioid-blocker and let the brain's own learning mechanisms unwind the habit.

This ran against the grain of mainstream alcohol treatment, which for most of the 20th century focused on abstinence, willpower and support groups. Sinclair's work suggested the biology of drinking was more tractable than anyone had assumed.

The opioid-reward pathway

When you drink, the brain releases its own opioid-like chemicals, endorphins, which bind to mu-opioid receptors. Those receptors then trigger dopamine release in the nucleus accumbens, the brain's reward centre. Over time, the brain learns to associate drinking with a reliable reward, and the learning strengthens every time you drink.

Naltrexone and nalmefene are opioid antagonists. They sit at the mu-opioid receptor but don't activate it. While they're in your system, the endorphin reward from alcohol is blocked. The drinking still happens; the dopamine reward does not.

Extinction: the key mechanism

This is Pavlovian in its simplicity. A learned behaviour persists as long as it's paired with a reward. Remove the reward, and the behaviour weakens. Every drinking episode on naltrexone is, in brain-learning terms, an extinction trial. Every drinking episode without it is a reinforcement trial.

This is why the method works when you drink with it in your system, not when you don't. The drinking event itself is what does the unlearning. This is also why timing matters: you take naltrexone one hour before drinking so it's at peak concentration as you start to drink.

Most patients begin to notice their urge quiet within 4-6 weeks. Full extinction typically takes 3-4 months of consistent use.

The evidence base

Over ninety clinical trials have examined naltrexone in alcohol use disorder. Key reviews:

• 2023 JAMA systematic review and meta-analysis (McPheeters et al.): 118 trials, 20,976 participants. Oral naltrexone 50mg significantly reduced heavy drinking versus placebo. Number needed to treat to prevent return to heavy drinking: 11.

• 2014 JAMA systematic review (Jonas et al.): naltrexone reduced return to heavy drinking with moderate strength of evidence.

• Cochrane 2010 review (Rösner et al.): opioid antagonists reduced heavy drinking days; effect particularly strong in patients with high craving.

• Sinclair 2001 paper in Alcohol and Alcoholism: the foundational paper summarising the 90+ laboratory and clinical studies underpinning the method.

The evidence is not perfect, and more recent trials tend to show slightly smaller effects than older ones — most likely reflecting improved placebo controls and stricter reporting. But the direction of effect is consistent and the biology is well-understood.

Why some people don't respond

Roughly 78-80% of people who adhere to the method see meaningful reduction. About one in five don't. The honest reasons are:

• Genetic variation at the mu-opioid receptor (OPRM1 A118G polymorphism): some people's receptors respond differently to naltrexone.

• Drinking that is habit-driven or socially-driven rather than reward-driven. If you drink because you always drink on Tuesdays with your neighbour, blocking the reward may not change much.

• Concurrent use of other reward-driving substances (heavy smoking, stimulants, cannabis) that keep the pleasure circuitry active.

• Untreated or inadequately-treated mental health conditions (depression, trauma, anxiety) that drive drinking independent of reward.

• Poor compliance. This is the biggest single factor. Taking the tablet 80% of the time is materially different from taking it 30% of the time.

We screen for these things during your consultation. For patients who don't respond after a fair trial, we'll have an honest conversation about what else might help — whether that's switching to nalmefene, adding psychological therapy, or recommending an abstinence-based pathway.

Naltrexone versus nalmefene

Both are opioid antagonists with the same core mechanism. Key differences:

• Licensing: naltrexone is prescribed off-label for TSM in the UK (licensed for opioid dependence); nalmefene has a UK marketing authorisation specifically for alcohol reduction (NICE TA325).

• Dosing: naltrexone 50mg taken 1 hour before drinking; nalmefene 18mg taken 2 hours before.

• Half-life: naltrexone ~8-10 hours; nalmefene ~12-14 hours. Nalmefene covers a longer drinking session on a single dose.

• Liver: naltrexone is metabolised mostly hepatically and can occasionally cause transient LFT changes; nalmefene is considered kinder to the liver and doesn't require routine LFT monitoring.

• Tolerability: broadly similar. Nalmefene's side effects can be more severe in the first week but settle similarly.

In our practice, naltrexone is the default because it's cheaper, better-studied and the protocol is simpler. Nalmefene is our preferred alternative for patients with mildly deranged LFTs, patients who tolerate naltrexone poorly, or patients whose drinking pattern suits as-needed dosing.

How TSM compares with other alcohol medications

Acamprosate works on GABA-glutamate systems and is designed to help patients who have already stopped drinking stay stopped. It isn't a fit for anyone who wants to reduce rather than abstain.

Disulfiram (Antabuse) works by making you violently ill if you drink. It depends entirely on willpower to take it every day, and the evidence base is small. Very different philosophy.

Naltrexone and nalmefene are the only licensed medications that support a reduction-not-abstinence approach with meaningful supporting evidence. That's why the Sinclair Method exists.

What happens physiologically over 3-4 months

The short version: every drinking-while-on-naltrexone episode weakens the reward association slightly. Over weeks, the dopamine peaks get smaller. Over months, the urge itself quiets. The number of units per drinking session tends to fall first, followed by the frequency of drinking occasions. Many patients report that drinking simply stops feeling as appealing — they reach for a second drink less often because the first didn't deliver the expected lift.

The extinction is durable as long as you keep the pairing intact. That means that if you stop taking naltrexone entirely and keep drinking, the old reward association can re-form. Most patients stay on naltrexone through the programme and then taper or stop once their drinking has settled at a comfortable level.

The references

• Sinclair JD. Evidence about the use of naltrexone and for different ways of using it in the treatment of alcoholism. Alcohol and Alcoholism, 2001;36(1):2-10.

• McPheeters M et al. Pharmacotherapy for Alcohol Use Disorder: A Systematic Review and Meta-Analysis. JAMA, 2023.

• Jonas DE et al. Pharmacotherapy for adults with alcohol use disorders in outpatient settings. JAMA, 2014.

• Mann K et al. Extending the treatment options in alcohol dependence: a randomized controlled study of as-needed nalmefene. Biological Psychiatry, 2013.

• NICE TA325: Nalmefene for reducing alcohol consumption in people with alcohol dependence. 2014.

• NICE CG115: Alcohol-use disorders: diagnosis, assessment and management of harmful drinking and alcohol dependence.

• Eskapa R. The Cure for Alcoholism. BenBella Books, 2008 (lay explanation of the method for patients and families).